
Balchem (BCPC) Stock Forecast & Price Target
Balchem (BCPC) Analyst Ratings
Bulls say
Balchem Corp is projected to experience continued earnings growth, with anticipated GAAP earnings of $4.73 per diluted share for 2025 and $5.17 per diluted share for 2026, reflecting positive momentum in its Human Nutrition and Health segment. The company's second quarter 2025 financial results showcased a top-line revenue of $255.5 million, exceeding estimates and marking a 1% increase from the previous year, alongside sequential growth. Additionally, improvements in gross and net margins, coupled with a strong balance sheet that may lead to the company becoming debt-free by the end of next year, position Balchem favorably for potential accretive mergers and acquisitions.
Bears say
Balchem Corp's stock outlook is negatively impacted by several fundamental factors, including a decline in the applicable price-to-earnings (P/E) multiple to 37.9x from 39.6x, signaling weakening market sentiment. The company faces multiple risks such as slower-than-expected growth in its core businesses, ongoing inflationary pressures, and potential disruptions in European operations due to regional conflicts. Additionally, the company's recent performance in its Animal Health and Nutrition segment fell short of expectations, with reported sales of $56.4 million against an estimated $60 million, further exacerbating concerns regarding its future revenue generation capabilities.
This aggregate rating is based on analysts' research of Balchem and is not a guaranteed prediction by Public.com or investment advice.
Balchem (BCPC) Analyst Forecast & Price Prediction
Start investing in Balchem (BCPC)
Order type
Buy in
Order amount
Est. shares
0 shares